Eric Masson

4.9k total citations · 1 hit paper
118 papers, 4.1k citations indexed

About

Eric Masson is a scholar working on Organic Chemistry, Oncology and Molecular Biology. According to data from OpenAlex, Eric Masson has authored 118 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Organic Chemistry, 37 papers in Oncology and 27 papers in Molecular Biology. Recurrent topics in Eric Masson's work include Supramolecular Chemistry and Complexes (28 papers), Crystallography and molecular interactions (18 papers) and Colorectal Cancer Treatments and Studies (16 papers). Eric Masson is often cited by papers focused on Supramolecular Chemistry and Complexes (28 papers), Crystallography and molecular interactions (18 papers) and Colorectal Cancer Treatments and Studies (16 papers). Eric Masson collaborates with scholars based in United States, Germany and United Kingdom. Eric Masson's co-authors include Xiaoyong Lu, Xiaoxi Ling, Roymon Joseph, Dirk Laurent, Mary V. Relling, William E. Evans, John D. Schuetz, Amit Roy, Feng Yan and Manfred Schlosser and has published in prestigious journals such as Nature, Journal of the American Chemical Society and Angewandte Chemie International Edition.

In The Last Decade

Eric Masson

113 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cucurbituril chemistry: a tale of supramolecular success

2011 826 citations Eric Masson, Roymon Joseph et al. profile →

Peers

Countries citing papers authored by Eric Masson

Since Specialization

Citations

This map shows the geographic impact of Eric Masson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Masson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Masson more than expected).

Fields of papers citing papers by Eric Masson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Masson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Masson. The network helps show where Eric Masson may publish in the future.

Co-authorship network of co-authors of Eric Masson

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Masson. A scholar is included among the top collaborators of Eric Masson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Masson. Eric Masson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	2D Ionic Liquid‐Like State of Charged Rare‐Earth Clusters on a Metal Surface 2024 ·Advanced Science ·Daniel J. Trainer, Alex Taekyung Lee, (unknown), Vijay Singh, (unknown), Naveen K. Dandu, (unknown), Shaoze Wang, (unknown), (unknown), (unknown), Larry A. Curtiss, Sergio E. Ulloa, Anh T. Ngo, Eric Masson, Saw‐Wai Hla	3
2	Solvent-controlled formation of alkali and alkali-earth-secured cucurbituril/guest trimers 2023 ·Chemical Science ·(unknown), (unknown), (unknown), Martin Dračínský, Josef Cvačka, Shanshan Guan, Benjamin J. Bythell, Ivana Cı́sařová, Eric Masson, Jiřı́ Kaleta	4
3	Characterization of just one atom using synchrotron X-rays 2023 ·Nature ·(unknown), Nozomi Shirato, Tomás Rojas, Sarah Wieghold, (unknown), (unknown), Daniel J. Trainer, Naveen K. Dandu, Yiming Li, (unknown), (unknown), Daniel Rosenmann, Yuzi Liu, Nathalie Kyritsakas, Shaoze Wang, Eric Masson, Volker Rose, Xiaopeng Li, Anh T. Ngo, Saw‐Wai Hla	45
4	Amplified spontaneous emission from europium-based molecular complexes coupled to photonic crystal cavities 2023 ·Applied Physics Letters ·(unknown), (unknown), A.D. Smith, Eric Masson, David J. Gosztola, Tijana Rajh, Saw‐Wai Hla, Xuedan Ma	1
5	X-ray Spectroscopy of a Rare-Earth Molecular System Measured at the Single Atom Limit at Room Temperature 2023 ·The Journal of Physical Chemistry C ·Sarah Wieghold, Nozomi Shirato, (unknown), (unknown), Daniel J. Trainer, (unknown), Daniel Rosenmann, Eric Masson, Volker Rose, Saw‐Wai Hla	2
6	Atomically precise control of rotational dynamics in charged rare-earth complexes on a metal surface 2022 ·Nature Communications ·(unknown), Vijay Singh, (unknown), (unknown), (unknown), (unknown), Naveen K. Dandu, Shaoze Wang, (unknown), Sarah Wieghold, Nozomi Shirato, Volker Rose, Larry A. Curtiss, Anh T. Ngo, Eric Masson, Saw‐Wai Hla	13
7	Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis 2018 ·Journal of Cancer Research and Clinical Oncology ·Howard L. Kaufman, Lawrence H. Schwartz, William N. William, Mario Sznol, Kyle Fahrbach, Yingxin Xu, Eric Masson, (unknown)	23
8	Clinical Pharmacokinetics and Pharmacodynamics of Cediranib 2016 ·Clinical Pharmacokinetics ·Weifeng Tang, Alex McCormick, Jianguo Li, Eric Masson	22
9	Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma 2013 ·Clinical Cancer Research ·Feng Yan, Amit Roy, Eric Masson, Tai‐Tsang Chen, Rachel Humphrey, Jeffrey S. Weber	145
10	Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. 2013 ·PubMed Central ·Jeffrey S. Weber, Omid Hamid, Asim Amin, Steven O’Day, Eric Masson, S. Goldberg, (unknown), Susan Parker, Scott D. Chasalow, Suresh Alaparthy, Jedd D. Wolchok	58
11	Subtle “supramolecular buttressing effects” in Cucurbit[7]uril/guest assemblies 2013 ·Organic & Biomolecular Chemistry ·Roymon Joseph, Eric Masson	12
12	Metabolism and Disposition of [14C]Brivanib Alaninate after Oral Administration to Rats, Monkeys, and Humans 2011 ·Drug Metabolism and Disposition ·Jiachang Gong, Jinping Gan, Janet Caceres‐Cortes, Lisa J. Christopher, Vinod Arora, Eric Masson, (unknown), Janice Pursley, Alban J. Allentoff, Michael W. Lago, (unknown), Ramaswamy A. Iyer	13
13	Targeting Protein–Protein Interactions: Suppression of Stat3 Dimerization with Rationally Designed Small‐Molecule, Nonpeptidic SH2 Domain Binders 2008 ·ChemBioChem ·Patrick T. Gunning, Matthew P. Glenn, Khandaker Siddiquee, William P. Katt, Eric Masson, Saı̈d M. Sebti, James Turkson, Andrew D. Hamilton	41
14	A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer 2007 ·Annals of Oncology ·Anne Thomas, Tanja Trarbach, (unknown), Dirk Laurent, Andrew Henry, (unknown), Jim J. Wang, Eric Masson, W P Steward, U. Vanhoefer, Bertram Wiedenmann	40
15	Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome 2006 ·Leukemia ·Gail J. Roboz, Francis J. Giles, Alan F. List, Jörge E. Cortes, Rebecca F. Carlin, Michał Kowalski, Sanela Bilic, Eric Masson, Marianne Rosamilia, Michael W. Schuster, Dirk Laurent, Eric J. Feldman	65
16	A Phase I, open-label study with escalating doses of intravenous PTK787/ZK 222584, a multi-VEGF receptor inhibitor, followed by multiple oral daily dosing to assess the absolute bioavailability of PTK787/ZK 222584 after single and multiple doses in advanced cancer patients 2005 ·European Journal of Cancer Supplements ·Marianne Pavel, (unknown), L.M. Jost, Darcy A. Kerr, (unknown), T. Jalava, Eric Masson, (unknown), (unknown)	2
17	Effects of Rifabutin and Rifampicin on the Pharmacokinetics of Ethinylestradiol and Norethindrone 1998 ·The Journal of Clinical Pharmacology ·Marc Lebel, Eric Masson, (unknown), (unknown), F. Paquet, (unknown), François Vallée, Prem K. Narang	48
18	Differences in Folylpolyglutamate Synthetase and Dihydrofolate Reductase Expression in Human B-Lineage versus T-Lineage Leukemic Lymphoblasts: Mechanisms for Lineage Differences in Methotrexate Polyglutamylation and Cytotoxicity 1997 ·Molecular Pharmacology ·(unknown), John D. Schuetz, Eric Masson, Yuri Yanishevski, Timothy W. Synold, Julio C. Barredo, Ching‐Hon Pui, Mary V. Relling, William E. Evans	86
19	Allopurinol inhibits de novo purine synthesis in lymphoblasts of children with acute lymphoblastic leukemia. 1996 ·PubMed ·Eric Masson, Timothy W. Synold, Mary V. Relling, John D. Schuetz, J T Sandlund, Ching‐Hon Pui, Evans We	16
20	Favorable Pharmacodynamic Features and Superior Anti-Leukemic Activity of B43 (Anti-CD 19) Immunotoxins Containing Two Pokeweed Antiviral Protein Molecules Covalently Linked to each Monoclonal Antibody Molecule 1995 ·Leukemia & lymphoma ·Dorothea E. Myers, Yuri Yanishevski, Eric Masson, James D. Irvin, William E. Evans, Fatih M. Uckun	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact